Enzalutamide, a novel androgen receptor (AR) antagonist, prolongs overall survival of
patients with castration-resistant prostate cancer (CRPC); however, patients eventually …

Background Sorafenib promotes apoptosis through downstream pathways that can be
deregulated in CRPC. We hypothesized that sorafenib could overcome chemotherapy …

Purpose The objective of this trial was to evaluate the clinical effects of sorafenib, a multi-
targeted kinase inhibitor, in combination with androgen receptor blockade in patients with …

BACKGROUND Enzalutamide (formerly MDV3100 and available commercially as Xtandi®),
a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration‐resistant …

Purpose We performed a dose-escalation study to investigate the safety of sorafenib in
combination with docetaxel and prednisone in chemo-naïve patients with metastatic …

Castrate-resistant prostate cancer (CRPC) is challenging to treat, despite improvements with
next-generation anti-androgens such as enzalutamide, due to acquired resistance. One of …

The treatment options for patients with castration-resistant prostate cancer (CRPC), until very
recently, only included docetaxel. In the past 10 months, newly Federal Drug Administration …

Abstract Treatment options for metastatic castration-resistant prostate cancer (CRPC) have
evolved with the established benefit of the novel androgen receptor (AR)-targeted agents …

Until 2010 docetaxel was the only agent with a proven survival benefit in the treatment of
castration-resistant prostate cancer (CRPC). Recent evidence suggests that CRPC is …

These findings were really interesting and important. It was very clever to investigate the
progression sequence of mCRPC by analyzing the different tumors collected at different time …